Rodin Therapeutics
Rodin Therapeutics was a biotechnology company that developed treatments for Alzheimer's disease. Founded in 2013, it was acquired in 2019 by Alkermes.
All edits
Rodin Therapeutics
Rodin Therapeutics iswas a biotechnology company developingthat developed treatments for Alzheimer's diseaseAlzheimer's disease that. is headquarteredFounded in Cambridge2013, Massachusetts andit was foundedacquired in 20132019 by Ankit Mahadevia and Martin JefsonAlkermes.
Rodin Therapeutics iswas a biotechnology company developingthat developed therapies for neurological disorders by applying insights gained from epigenetics. The company was founded by Ankit Mahadevia and Martin Jefson in 2013, and iswas headquartered in Cambridge, Massachusetts. In November 2019, Rodin Therapeutics was acquired by Alkermes.
On June 27, 2013 Rodin Therapeutics closed their seed funding round with an undisclosed amount of funding from Johnson & Johnson Development Corporation and Atlas Venture.
On May 29, 2014 Rodin Therapeutics closed their series A funding round raising $12.9 million is funding from Johnson & Johnson Development Corporation and Atlas Venture.
On January 6, 2016 Rodin Therapeutics closed their series B funding round raising $17.3 million in funding from Biogen Idec and Atlas Ventures.
On September 18, 2017 Rodin Therapeutics closed their series C funding round raising $27 million in funding from Third Point Ventures, Remeditex Ventures, Hatteras Venture Partners, GV, and Atlas Ventures. In addition to closing their series C funding round Rodin Therapeutics appointed three new members to their Board of Directors.
On June 27, 2013 Rodin Therapeutics closed their seed funding round with an undisclosed amount of funding from Johnson & Johnson Development Corporation and Atlas Venture.
On May 29, 2014 Rodin Therapeutics closed their series A funding round raising $12.9 million is funding from Johnson & Johnson Development Corporation and Atlas Venture.
On January 6, 2016 Rodin Therapeutics closed their series B funding round raising $17.3 million in funding from Biogen Idec and Atlas Ventures.
On September 18, 2017 Rodin Therapeutics closed their series C funding round raising $27 million in funding from Third Point Ventures, Remeditex Ventures, Hatteras Venture Partners, GV, and Atlas Ventures. In addition to closing their series C funding round Rodin Therapeutics appointed three new members to their Board of Directors.
Find more companies like Rodin Therapeutics
